The recombinant prostate-specific PPT sequence comprises a prostate-specific antigen enhancer, a PSMA enhancer and a TARP promoter. It is transcriptionally active in human prostate cancer cells both in the presence and absence of testosterone. However, in experimental murine prostate cancer, it has no detectable transcriptional activity. Herein, we describe that the PPT sequence in combination with a two-step transcriptional amplification (TSTA) system becomes active also in murine prostate cancer cells. 
Introduction
The ability to target gene expression to tumor cells is an essential prerequisite for safe and effective cancer gene therapy. 1 The use of tumor-specific promoters to control expression of cytotoxic genes is an attractive strategy to target gene expression to tumor cells. Tissue-specific promoters may be used as well if the tumor originates from an organ that is not essential for life. The majority of the tumor-or tissue-specific promoters used in gene therapy are transcriptionally weak when compared to constitutively active viral promoters, such as the immediate early human cytomegalovirus (CMV) promoter, and may be unable to drive gene expression in the tumor cells to efficient therapeutic levels. Therefore, it is desirable to use methods to enhance the transcriptional activity of such promoters while maintaining tissue-specificity. The two-step transcriptional amplification (TSTA) system is a promising strategy to augment the transcriptional activity of tissue-specific promoters. In the TSTA system, the tissue-specific promoter controls a synthetic transcriptional activator consisting of a DNA binding domain from the yeast transcription activator GAL4 and two VP16 activation domains from the herpes simplex virus (HSV), GAL4-2xVP16. 2 The GAL4-2xVP16 in turn activates the gene of interest in a second expression cassette through a minimal GAL4 responsive promoter. By using this strategy, the PSE sequence, that is, the prostate-specific antigen (PSA) promoter with the upstream PSA enhancer, was upregulated 50-fold. 3 TSTA amplification of the vascular endothelial growth factor promoter has also been reported. 4 The transgenic adenocarcinoma of the mouse prostate (TRAMP) model is a widely used in vivo model of prostate cancer, as the tumor progression resembles the human disease. 5 To increase the versatility of the TRAMP model, three cell lines have been established from primary TRAMP tumors, TRAMP-C1, -C2 and -C3. 6 The TRAMP-C2 cell line is highly tumorigenic when grafted into syngenic C57Bl/6 hosts and valuable tool for experimental prostate cancer gene therapy in an immunocompotent host. 6 We have previously described the gene promoter for the T-cell receptor g-chain alternate reading frame protein (TARP). 7 Furthermore, we have produced an adenoviral vector where luciferase gene expression is controlled by a regulatory sequence comprising the PSA enhancer, the PSMA enhancer and the TARP promoter (named PPT), shielded from interfering adenoviral sequences by the mouse H19 insulator. 8 This vector, Ad[I/PPT-Luc], yields high and prostate-specific transgene expression both in the presence and absence of testosterone in human prostate cancer cell lines, 8 whereas no expression was observed in TRAMP-C2 cells (unpublished data). Here, we describe the advantages of using the PPT regulatory sequence together with the TSTA system. An adenoviral vector with PPT-controlled transgene expression amplified with TSTA exhibits prostate-specific enhancement of transcriptional activity in human cell lines. Furthermore, it confers high expression in murine TRAMP-C2 cells. By using a cooled optical charge-coupled device (CCD) camera system, luciferase expression was detected both in the LNCaP prostate cancer xenograft model and in the syngenic TRAMP-C2 prostate cancer model.
Materials and methods

Cell lines
Human cell lines. The prostate adenocarcinoma cell lines LNCaP (ATCC, Rockville, MD), PC-346C (a kind gift from Dr C Bangma, Erasmus University, Rotterdam, The Netherlands) and PC-3 (ATCC); the colon carcinoma HT29 and the glioma U343 cell lines (kind gifts from Dr J Carlsson, Uppsala University, Uppsala, Sweden) were cultured in Roswell Park Memorial Institute media (RPMI) 1640 supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 10 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES) and 1 mM sodium pyruvate. The endocrine pancreatic tumor cell line Bon (a kind gift from Dr JC Thompson, Galveston, TX) was cultured in Dulbecco's modified Eagle's medium (DMEM):F12 K nutrient mixture at a 1:1 ratio, supplemented with 10% FBS and 1 mM sodium pyruvate. The foreskin fibroblast cell line 1064SK was cultured in DMEM supplemented with 5% FBS and 2 mM Lglutamine. The aortic endothelial cell line HAEC was cultured in Medium 200 (Cascade Biologics, Portland, OR) supplemented with Low Serum Growth Supplement Kit (Cascade Biologics).
Murine cell lines. The prostate adenocarcinoma cell line TRAMP-C2, (a kind gift from Dr N Greenberg, Baylor College, Houston, TX) was cultured in DMEM supplemented with 5% FBS, 5% NuSerum (Becton Dickinson, Bedford, MA), 1 nM dihydrotestosterone (Sigma, St Louis, MO) and 5 mg/ml insulin (Sigma). The prostate adenocarcinoma cell lines, RM-1 and RM-9 (kind gifts from Dr T Thompson, Baylor College, Houston, TX), the mammary tumor cell line NMuMG (a kind gift from Dr A Moustakas, Ludwig Institute for Cancer Research, Uppsala, Sweden) the fibroblast cell line TIB-81 (ATCC) and bladder carcinoma cell line MB49 (a kind gift from Dr K Esuvaranathan, National University of Singapore, Singapore) were cultured in DMEM supplemented with 10% FBS. The bladder carcinoma cell line MBT2 was cultured in RPMI 1640 supplemented with 10% FBS.
Steroid-depleted cell culture medium was RPMI 1640 supplemented with 5% charcoal/dextran-treated FBS (Hyclone, Logan, UT), 2 mM L-glutamine, and 10 mM HEPES and 1 mM sodium pyruvate. All cell culture reagents, except when stated differently, were from Invitrogen (Carlsbad, CA).
Recombinant adenoviruses and viral transduction
The TSTA-based plasmid pBCVP265-Luc was a kind gift from Dr L Wu (UCLA, Los Angeles, CA). The PSE sequence was removed from pBCVP265-Luc by NheI digestion followed by Klenow DNA I polymerase treatment, to make blunt end DNA, and subsequent KpnI digestion. In parallel, the PPT regulatory sequence was excised from the luciferase reporter plasmid PSAe/ PSMAe/TARPp 8 by HindIII digestion followed by Klenow DNA I polymerase treatment and KpnI digestion. The excised PPT sequence was then subcloned in the KpnI/blunted site of pBCVP265-Luc to generate pPPT/ TSTA-Luc. The Ad[PPT/TSTA-Luc] vector was produced by excising the PPT/TSTA fragment from pPPT/ TSTA-Luc and subcloned it into the NotI/SalI site of pShuttle, which was subsequently recombined with pAdEasy1 (kind gifts from Dr B Vogelstein, Johns Hopkins, Baltimore, MD) using the AdEasy system. 9 The Ad[PPT-Luc], Ad[I/PPT-Luc] and Ad[CMV-Luc] vectors were constructed as described previously. 8 Adenoviruses were produced in 911 cells (Crucell, Leiden, The Netherlands), purified by CsCl banding and dialyzed against a buffer containing 10 mM Tris-HCl, pH 8.0, 2 mM MgCl 2 and 4% sucrose. Viruses were aliquoted and stored at À801C. Virus titers were determined by a fluorescenceforming unit (FFU) assay that has been verified to give comparable titers to a standard plaque-forming unit assay. Briefly, 911 cells were plated on collagen-coated 35 mM plates with grids (Sarstedt, Numbrecht, Germany) and infected with purified virus at various dilutions. The cells were cultured for 48 h, washed with PBS, fixed in 4% paraformaldehyd in PBS, washed once with PBS and once with PBS with 0.05% Tween-20 and incubated with a mouse monoclonal anti-adenovirus antibody (MAB8052, Chemicon, Temecula, CA) diluted 1:250 in PBS. After 2 h of incubation at RT, the cells were washed twice with PBS and once with PBS with 0.05% Tween-20 and incubated with a secondary fluorescein isothiocyanate-labeled rabbit polyclonal anti-mouse F(ab 0 ) 2 (DakoCytomation, Glostrup, Denmark) diluted 1:100 in PBS. After 2 h of lightprotected incubation at RT, the cells were washed twice in PBS and green cells were counted using an inverted phase contrast microscope with a fluorescence illuminator (Olympus, CK40).
The human cell lines were transduced in suspension at a multiplicity of infection (MOI) as follows: LNCaP, 50; PC-346C, 10; PC-3, 50; U343, 10; Bon, 10; HT29, 100; HAEC, 10; 1064SK, 50. All murine cell lines were transduced in suspension at an MOI of 500. Two hours after transduction, the medium was replaced with fresh steroid-depleted medium with or without 10 nM R1881 and the cells were incubated for 48 h before analysis.
Luciferase reporter gene assays in vitro
Luciferase activities were measured in triplicate samples as suggested by the manufacturer (Pharmingen, San Diego, CA). Briefly, transduced cells were lysed with lysis buffer (Pharmingen) and cell debris was removed by centrifugation. Supernatants were transferred to a whitebottom 96-well plate and substrate buffers A and B (Pharmingen) were mixed (1:1) and added for luciferase activity determination using the Wallac VICTOR 
Results
The PPT/TSTA expression cassette mediates high and prostate-specific transcriptional activity The PPT/TSTA-Luc system is schematically outlined in Figure 1a . The PPT regulatory sequence drives the expression of the synthetic transcription activator GAL4-2xVP16. The synthesized fusion protein acts on a promoter with five GAL4-response elements controlling luciferase gene expression. The PPT/TSTA-Luc expression cassette was introduced into the E1 position of an E1-and E3-deleted adenoviral vector. The adenoviral vector constructs used are schematically outlined in Abbreviation: cps, counts per second. (Figure 3c ). In conclusion, the TSTA system considerably increases the transcriptional activity of the PPT regulatory sequence in a prostate-specific and hormone-independent manner both in human and murine cells.
TSTA augments the transcriptional activity of PPT in prostate cancer cells in vivo As we observed augmented transcriptional activity in both human and murine prostate cancer cells in vitro, we wanted to explore the PPT activity in vivo as well. Abbreviation: cps, counts per second. (Figure 4b) . A representative example of a pair of mice with equal-sized tumors is shown in Figure 4d .
Discussion
We have previously demonstrated that PPT is a potent prostate-specific regulatory sequence that is transcriptionally active both in the presence and absence of testosterone. 8, 10 In this study, we describe the augmentation of the PPT regulatory sequence in murine and human prostate cancer cell lines by using the TSTA amplification system. The susceptibility of a cell line to human adenoviral serotype 5 vector infection is dependent on the cell surface expression of coxsackievirus and adenovirus receptor (CAR) 11, 12 and aV integrins. Therefore, for in vitro experiments, 10-to 50-fold higher MOI is generally needed to infect murine cells compared to human cells. We determined relative infectivity of different cell lines by normalization to the activity of Ad[CMV-Luc], in which luciferase expression is driven by the constitutively active CMV promoter. For simplicity, we compared the normalized luciferase activity to that of Ad[CMV-Luc], set at 100%.
We found that Ad[PPT/TSTA-Luc] mediates up to 100-fold higher transcriptional activity in vitro than a nonamplified PPT-based adenovirus in human prostate cancer cells. The activity is still prostate specific and independent of testosterone level in the culture media. Remarkably, Ad[PPT/TSTA-Luc] shows three-to ninefold higher expression levels of the luciferase reporter gene compared to Ad[CMV-Luc] in human prostate cancer cell lines. Iyer et al.
2 used a TSTA-containing plasmid to amplify the PSE regulatory sequence in LNCaP cells. 2 The PSE/TSTA cassette has since then been inserted both into an adenoviral vector 13 and a lentiviral vector 14 with significant amplification of the PSE transcriptional activity. The recombinant prostatespecific ARR 2 PB promoter, 15 developed from repeated elements from the rat probasin promoter, has been used together with a tetracycline response element to obtain prostate-specific transcription enhancement. 16 The PSE and ARR 2 PB sequences are however dependent on a functional androgen receptor signaling pathway and may not be suitable in a therapeutic setting for hormonerefractory prostate cancer. The Ad[PPT/TSTA-Luc] vector yields, on the contrary, high luciferase expression independently of the hormonal level. This feature makes the PPT/TSTA sequence highly interesting to use in a prostate cancer gene therapy setting.
We did not detect any luciferase activity from Ad[PPTLuc] or Ad[I/PPT-Luc] in the murine prostate cancer cell line TRAMP-C2, indicating that the recombinant PPT promoter is either not active in TRAMP-C2 or its activity is below detection limit in this particular assay. As TSTA amplification has been successfully used to enhance weak promoters, 4 we wanted to investigate whether TSTA could bring the activity of the PPT promoter above detection limit in TRAMP-C2. Interestingly, Ad[PPT/ TSTA-Luc] yielded an activity up to 23% of Ad[CMVLuc] in TRAMP-C2 without showing any activity in other murine non-prostate cell lines, indicating that the PPT promoter is in fact both active and specific in TRAMP-C2. Presumably, multiple copies of the GAL4-2xVP16 One of the applications where enhanced tissue-specific transcriptional activity is preferable is in imaging technologies that use bioluminescent or fluorescent reporter genes to produce a signal from within a living animal. The imaging offers real-time information on biological processes in vivo and images may be monitored over multiple time points. The usefulness of TSTA amplified transcription combined with in vivo imaging of luciferase expression has been implicated in numerous publications. 3, 13, 14, 17 Herein, we show augmented PPT promoter activity with the TSTA system in LNCaP xenograft tumors as well as in syngenic TRAMP-C2 tumors. It should be noted that the activity of Ad[PPT/TSTA-Luc] is more than three logs higher in the human xenogenic LNCaP model than in the murine syngenic TRAMP-C2 model. This is partly due to the fact that PPT has lower activity in TRAMP-C2 than in LNCaP cells and partly due to that murine cells lack human CAR receptors. Nevertheless, TSTA amplification brings PPT-driven luciferase expression above detection limit also in the syngenic murine in vivo model. To our knowledge, this is the first time the TSTA system and in vivo imaging have been used to induce and study prostate-specific expression in immunocompetent mice.
Our current study was conducted utilizing luciferase as a reporter gene. However, this reporter gene may be exchanged or used together with toxic transgenes. Candidate genes for treatment of prostate cancer include apoptotic genes such as tumor necrosis factor-related apoptosis-inducing ligand and Bax 18 and suicide genes such as HSV thymidine kinase and cytosine-deaminase. 19 One important feature of Ad[PPT/TSTA-Luc] is that it may be used both in xenograft models and immunocompetent mouse models with syngenic tumors such as the s.c. TRAMP-C2 model. Importantly, the latter opens up for studies of interaction between the host immune system and the effects of a transgene in a gene therapy vector before it is taken into clinical trials. The probasin promoter is also active in murine prostate making it possible to create transgenic mice such as TRAMP. 5 However, there are no reports on ARR 2 PB activity in murine prostate cancer cell lines. To our knowledge, this is the first prostate-specific construct that is transcriptionally active both in murine and human prostate cancer cell lines. Moreover, unlike ARR 2 PB, the PPT/TSTA is not dependent on testosterone and therefore highly suitable for treatment of hormone-refractory prostate cancer.
In conclusion, we report herein the two-step amplification of the PPT regulatory sequence. An adenovirus with TSTA-amplified PPT activity confers prostate-specific testosterone-independent transgene expression in human and murine cell lines, both in vitro and in vivo.
